Skip to content
Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 9, 2026

Omeros Corp (OMER)

A forensic read on Omeros Corp built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

F · Poor — capital at risk
Forensic grade
Distress
Financial health
-9.2
Distress distance
1
Forensic signals

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Omeros Corp earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -9.2, placing it in the Distress zone. 1 forensic signal was flagged in its latest SEC filings, led by shareholder returns — halted.

What the filings flag

stopped
FY2024→FY2025
Shareholder returns — halted. Capital returns have STOPPED — $12M of buybacks + dividends in FY2024, but ~$0 in FY2025. A halt usually means the company is conserving cash.

Key fundamentals

Free Cash Flow-$116.2M

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Omeros Corp's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 9, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.